Searchable abstracts of presentations at key conferences in endocrinology

ea0037mte7 | (1) | ECE2015

Management of adrenal insufficiency

Hahner Stefanie

For a long time it has been assumed that patients with adrenal insufficiency (AI) can live without any restriction when receiving standard hormone replacement therapy.However, recent evidence indicates that subjective health status (SHS) in patients with primary adrenal insufficiency is significantly impaired at least in a subgroup of patients and that mortality is increased compared to the general population.The observation of imp...

ea0026s7.3 | Novel approaches to <emphasis role="italic">in vitro</emphasis> and <emphasis role="italic">in vivo</emphasis> imaging | ECE2011

Molecular and clinical imaging of adrenal steroidogenesis by iodometomidate

Hahner Stefanie

Molecular imaging technologies are emerging tools providing both researchers and clinicians with technologies for non invasive in vivo studies. Steroidogenic enzymes are abundantly and specifically expressed in steroidogenic tissue and represent an interesting target for tissue specific characterization. Iodometomidate is a highly potent inhibitor of cortisol and aldosterone synthesis due to specific and high affinity binding to both CYP11B1- and CYP11B2-enzymes. Our ai...

ea0021cm3.4 | Management of congenital adrenal hyperplasia across the lifespan | SFEBES2009

Quality of life in CAH: does it differ from adrenal insufficiency?

Hahner Stefanie

Quality of life (QoL) is significantly impaired in patients with primary and secondary adrenal insufficiency (AI) irrespective of the glucocorticoid dosing regimen or the currently available glucocorticoid preparation. The impairment of QoL has been particularly attributed to the unphysiological mode of glucocorticoid replacement, which only roughly resembles the physiological profile. In both congenital adrenal hyperplasia (CAH) and Addison's disease, failure in cortisol synt...

ea0081p762 | Late-Breaking | ECE2022

Do polymorphisms of the glucocorticoid and mineralocorticoid receptors play a role in adrenal crises?

Chifu Irina , Janik Freytag , Herterich Sabine , Heike Weber , Hahner Stefanie

Introduction: Polymorphisms of the glucocorticoid (NR3C1) and mineralocorticoid receptor (NR3C2) have been linked to the regulation of HPA-axis and to glucocorticoid sensitivity. We investigated whether NR3C1 and NR3C2 polymorphisms correlate with the occurence of adrenal crises (AC) in patients with primary adrenal insufficiency (PAI).Material and methods: We investigated 100 patients with PAI (70% women, mean age 51±15 years). DNA was extracted fr...

ea0038p407 | Steroids | SFEBES2015

Conventional vs modified release hydrocortisone in mitotane treated patients with adrenocortical cancer

Weigel Marianne , Hahner Stefanie , Beier Daniela , Zopf Kathrin , Quinkler Marcus

Background: Mitotane is a strong inducer of hepatic CYP3A4 activity (cortisol metabolism) and increases cortisol-binding globulin (CBG). High hydrocortisone dosages are necessary in patients with adrenocortical cancer (ACC) on mitotane treatment. The newly modified release hydrocortisone has not been used in mitotane-treated ACC patients yet.Aim: To compare cortisol (serum and saliva), calculated free serum cortisol and ACTH levels in ACC patients on mit...

ea0020s23.4 | Adrenocortical tumours – pathogenesis and management | ECE2009

Chemotherapy and radiotherapy for adrenocortical carcinoma (ACC)

Fassnacht Martin , Hahner Stefanie , Polat Buelent , Allolio Bruno

ACC is a rare, heterogeneous malignancy with poor prognosis. Data from the German ACC Registry (n=478) indicate a 5-year survival rate of 47%. In addition to mitotane, cytotoxic drugs are standard of care in advanced ACC. The best results have been reported by Berruti et al. for the combination of mitotane with etoposide, doxorubicin and cisplatin with an objective tumor response rate of 49% in 72 patients. A response rate of 36% was published for the combination...

ea0005p14 | Clinical Case Reports | BES2003

Combined pituitary hormone deficiency (CPHD) with adult-onset corticotropin deficiency but without evidence for PROP-1 or HESX1 mutations

Hammer F , Hahner S , Allolio B , Arlt W

Combined pituitary hormone deficiency (CPHD) denotes impaired production of growth hormone (GH) and of one or more other pituitary trophic hormones. Distinct subtypes of CPHD have been shown to be due to mutations in different homeobox transcription factors, which are involved in pituitary development and organogenesis. So far, only PROP-1 and HESX1 mutations have been associated with CPHD comprising corticotropin deficiency. Here we report two patients with a novel form of CP...

ea0081rc2.2 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

FKBP5 methylation in adrenal insufficiency: looking at a new tool for assessing the quality of glucocorticoid replacement?

Chifu Irina , Carolin Scheuermann , Stephanie Burger-Stritt , Lippert Juliane , Herterich Sabine , Hahner Stefanie

Available glucocorticoid (GC) replacement regimens in adrenal insufficiency (AI) only roughly correspond to physiological steroid profiles. Control of substitution quality is therefore difficult but significant, as even mild chronic over- or under-replacement may be clinically relevant. FKBP5 regulates GC receptor sensitivity by reducing its affinity to cortisol when bound to the receptor complex. FKBP5 methylation has been inversely correlated with cortisol levels both in hea...

ea0083ao3 | Adrenal and Cardiovascular | EYES2022

Looking for fingerprints of increased susceptibility to adrenal crises

I Chifu , S Burger-Stritt , S Herterich , H Weber , J Freytag , S Hahner

Background: Adrenal crises (AC) still occur even in educated patients with adrenal insufficiency. Identifying predisposing factors can improve risk assessment and facilitate prevention in this patient population.Objectives: Investigating clinical and biochemical fingerprints of increased susceptibility to AC.Material and methods: Our study population included 71 patients with adrenal insufficiency, classified in high and low risk a...

ea0090rc9.3 | Rapid Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Fingerprints of increased susceptibility to adrenal crises in patients with chronic adrenal insufficiency

Chifu Irina , Janik Freytag , Quinkler Marcus , Herterich Sabine , Stephanie Burger-Stritt , Hahner Stefanie

Background: Potentially fatal adrenal crises (AC) still occur in educated patients with adrenal insufficiency (AI). Identifying predisposing factors is necessary for prevention in this patient population.Objectives: Investigating clinical and biochemical fingerprints of increased susceptibility to AC.Material and methods: Our study population included 260 patients with chronic AI, classified as high and low risk according to the fr...